Effect of the somatostatin analog octreotide on gastric mucosal function and histology during 3 months of preoperative treatment in patients with acromegaly

Plöckinger, Ursula; Perez-Cantó, A; Emde, C; Rm, Liehr; Hopfenmüller, Werner; Quabbe, H.-J.

doi:10.1530/eje.0.1390387

Cited by 6 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Together with a direct inhibitory effect at the parietal cell of the gastric mucosa, gastric acid—and probably intrinsic factor secretion—is reduced. Thus there is an increased risk of chronic gastritis and, with long-term therapy, a decline of the vitamin B12 concentration [97, 98]. This may be compensated by a monthly intramuscular injection of cyanocobalamin.…”

Section: Options For Medical Therapymentioning

confidence: 99%

Medical Therapy of Acromegaly

Plöckinger

2012

International Journal of Endocrinology

View full text Add to dashboard Cite

This paper outlines the present status of medical therapy of acromegaly. Indications for permanent postoperative treatment, postirradiation treamtent to bridge the interval until remission as well as primary medical therapy are elaborated. Therapeutic efficacy of the different available drugs—somatostatin receptor ligands (SRLs), dopamine agonists, and the GH antagonist Pegvisomant—is discussed, as are the indications for and efficacy of their respective combinations. Information on their mechanism of action, and some pharmakokinetic data are included. Special emphasis is given to the difficulties to define remission criteria of acromegaly due to technical assay problems. An algorithm for medical therapy in acromegaly is provided.

show abstract

Section: Options For Medical Therapymentioning

confidence: 99%

Medical Therapy of Acromegaly

Plöckinger

2012

International Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Prophylactic therapy with chenodeoxy-cholic acid and ursodeoxy-cholic acid may be able to prevent the occurrence of gallstone disease in patients on long-term SSA therapy. Serum vitamin B12 concentration may decline, possibly due to a direct inhibition of the intrinsic factor secretion at the parietal cell [52].…”

Section: Somatostatin Analogues (Ssa)mentioning

confidence: 99%

Treatment of gastroenteropancreatic neuroendocrine tumors

Plöckinger

Wiedenmann

2007

Virchows Arch

View full text Add to dashboard Cite

Neuroendocrine tumors are rare; thus, individual experience with the diagnosis and treatment of these tumors is mostly low, except in specialized centers. For histological diagnosis, standards have been described recently. Pathological classification and clinical staging influence diagnostic and therapeutic decisions. This chapter aims at demonstrating the importance of pathological and clinical classification of neuroendocrine tumors on therapeutic decisions, indicating the appropriate therapy for different stages of the disease. Surgical therapy will be discussed shortly, including palliative surgical strategies. However, the focus of the manuscript is medical therapy. Biotherapy, its effects, and remaining uncertainties are presented as well as different chemotherapeutic schemes. Finally, new options of palliative medical therapies like kinase inhibitors and anti-angiogenetic drugs will be discussed.

show abstract